Enzon Pharmaceuticals Files 8-K: Material Agreement & More

Ticker: ENZN · Form: 8-K · Filed: Apr 1, 2025 · CIK: 727510

Sentiment: neutral

Topics: material-agreement, corporate-action, filing

TL;DR

Enzon Pharma filed an 8-K on 3/31/25 for a material agreement. Big moves ahead?

AI Summary

On March 31, 2025, Enzon Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also addresses modifications to security holder rights and includes financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing indicates significant corporate activity, potentially involving new agreements or changes affecting Enzon Pharmaceuticals' stakeholders.

Risk Assessment

Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce new risks or alter existing ones for investors.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement filed by Enzon Pharmaceuticals, Inc. on March 31, 2025?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.

What other items are covered in this 8-K filing besides the material definitive agreement?

The filing also covers material modifications to the rights of security holders and includes financial statements and exhibits.

When is Enzon Pharmaceuticals, Inc.'s fiscal year end?

Enzon Pharmaceuticals, Inc.'s fiscal year ends on December 31.

What is the Commission File Number for Enzon Pharmaceuticals, Inc.?

The Commission File Number for Enzon Pharmaceuticals, Inc. is 001-36435.

What is the IRS Employer Identification Number for Enzon Pharmaceuticals, Inc.?

The IRS Employer Identification Number for Enzon Pharmaceuticals, Inc. is 22-2372868.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding ENZON PHARMACEUTICALS, INC. (ENZN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing